Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Price Performance

Exact Sciences stock traded up $0.54 during mid-day trading on Friday, reaching $42.90. The company had a trading volume of 31,919 shares, compared to its average volume of 1,954,481. The stock's 50-day simple moving average is $44.06 and its 200-day simple moving average is $58.14. The company has a market capitalization of $7.59 billion, a P/E ratio of -10.01 and a beta of 1.32. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.48 and a quick ratio of 2.23. Exact Sciences has a 1 year low of $35.34 and a 1 year high of $108.99.

Analyst Upgrades and Downgrades

EXAS has been the subject of a number of recent analyst reports. StockNews.com raised Exact Sciences from a "sell" rating to a "hold" rating in a report on Tuesday, July 26th. Citigroup cut their price objective on shares of Exact Sciences from $65.00 to $50.00 and set a "neutral" rating on the stock in a report on Wednesday, August 3rd. Cowen lowered their target price on shares of Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a report on Wednesday, August 3rd. Robert W. Baird cut their price target on shares of Exact Sciences from $90.00 to $75.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 3rd. Finally, Cowen dropped their price objective on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and an average target price of $71.00.

Insider Activity

In other Exact Sciences news, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the transaction, the director now owns 60,318 shares in the company, valued at $2,420,561.34. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Exact Sciences news, Director Katherine S. Zanotti sold 1,086 shares of the stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the sale, the director now owns 60,318 shares in the company, valued at approximately $2,420,561.34. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Katherine S. Zanotti sold 4,608 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the transaction, the director now directly owns 60,318 shares of the company's stock, valued at $2,722,754.52. The disclosure for this sale can be found here. Insiders sold a total of 5,701 shares of company stock worth $251,872 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.